Followers | 145 |
Posts | 27565 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, October 07, 2020 12:11:33 PM
Oct. 7, 2020 12:07 PM ET|About: RedHill Biopharma Ltd. (RDHL)|By: Vandana Singh, SA News Editor
Independent Safety Monitoring Committee has completed second pre-scheduled safety review for RedHill Biopharma's (RDHL +4.1%) opaganib (Yeliva, ABC294640) U.S. Phase 2 study, in patients hospitalized with severe COVID-19 pneumonia, and recommended that the study continue unmodified.
The recommendation is based on an unblinded analysis of safety data from the first 24 patients treated in the study for at least seven days. The study is 75% enrolled.
The U.S. Phase 2 study looks to complete enrollment this month, with data expected to follow before the end of this year.
In parallel, the global Phase 2/3 study with opaganib in patients with severe COVID-19 pneumonia is on track to enroll up to 270 patients by the end of the year.
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 11:01:56 AM
- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study • PR Newswire (US) • 04/24/2024 11:00:00 AM
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights • PR Newswire (US) • 04/08/2024 01:23:00 PM
- RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price • PR Newswire (US) • 04/02/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 11:01:56 AM
- RedHill Announces New USPTO Patent Covering Talicia® Through 2034 • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:01:24 PM
- RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:05:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 12:01:50 PM
- RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 01:54:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/16/2024 05:15:18 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 09:05:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:10:29 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 03:22:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 05:50:54 PM
- RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering • PR Newswire (US) • 01/26/2024 05:46:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 02:31:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2024 02:29:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:09:10 PM
- RedHill Biopharma Announces $8 Million Registered Direct Offering • PR Newswire (US) • 01/25/2024 02:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 11:02:56 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM